Survival improvement of colorectal liver metastasis (CRLM) benefits from systemic therapy and metastasis-directed local therapy. Stereotactic ablative body radiotherapy (SABR), as a new efficient metastasis-directed local therapy with a systematic impact, plays a vital role in CRLM multidisciplinary treatment. SABR leads to a dramatic immunological change in the tumor microenvironment (TME) via differential activation of cytoprotective and cytotoxic pathways in malignant and non-malignant cells, in addition to direct tumor cell death. The synergy of SABR and immunotherapy might increase the abscopal response rate of out-field lesions by targeting different steps of the immune-mediated response, in addition to direct intratumoral cell death. The clinical treatment and efficacy of SABR, its influence on TME, and potential molecular underpinnings of which are the topic of this review.

结直肠肝转移（CRLM）的生存改善受益于全身治疗和转移导向的局部治疗。立体定向消融体放射治疗（SABR）作为一种具有系统影响的新型高效转移定向局部治疗，在CRLM多学科治疗中发挥着至关重要的作用。除了直接的肿瘤细胞死亡外，SABR 通过在恶性和非恶性细胞中的细胞保护和细胞毒性途径的差异激活，导致肿瘤微环境 (TME) 发生显着的免疫学变化。SABR 和免疫疗法的协同作用可能会通过针对免疫介导反应的不同步骤以及直接的肿瘤内细胞死亡来提高外场病变的远位反应率。SABR的临床治疗和疗效，其对TME的影响，